Proactive Investors - Run By Investors For Investors

Boston Scientific rises as preliminary 4Q sales figures match consensus estimate

For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion
A surgeon putting on gloves
For all of 2018, Boston Scientific reported a 8.6% gain in preliminary sales

Boston Scientific Corp (NYSE:BSX) advanced Tuesday after reporting preliminary fourth-quarter sales figures that were in line with the consensus estimate.

The Marlborough, Massachusetts-based medical products company said preliminary sales increased 6.3% on a reported based during the fourth quarter to $2.56 billion. That matched the average estimate of analysts.

READ: Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018

Shares of Boston Scientific rose $0.47, or 1.4%, to $34.89 in New York Stock Exchange trading.
 
For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion.

Highlights included a 10.9% gain in its urology and pelvic health segment and 6.4% growth in its cardiovascular business.

Contact Dennis Fitzgerald at [email protected]

View full BSX profile View Profile

Boston Scientific Timeline

Related Articles

harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use